Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
CA102N
DRUG
3 trials
Sponsors
Holy Stone Healthcare Co., Ltd
Conditions
Advanced or Metastatic Colorectal Cancer (mCRC)
Advanced or Metastatic Solid Tumors
Metastatic Colorectal Cancer
Phase 1
First-in-human Study of CA102N Monotherapy and CA102N Combined With Trifluridine/Tipiracil (LONSURF) in Subjects With Advanced Solid Tumors
Completed
NCT03616574
Holy Stone Healthcare Co., Ltd
Advanced or Metastatic Colorectal Cancer (mCRC), Advanced or Metastatic Solid Tumors
Start: 2019-04-09
End: 2022-03-01
Updated: 2022-09-21
Phase 2
Phase 2 Study of CA102N Combined With TAS-102 Compared to Bevacizumab Combined With TAS-102 in Subjects With Relapsed and/or Refractory Metastatic Colorectal Cancer
NCT06039202
Holy Stone Healthcare Co., Ltd
Metastatic Colorectal Cancer
Start: 2024-01-31
End: 2025-10-31
Target: 100
Updated: 2023-09-15
Unknown Phase
Individual Patient Expanded Access to CA102N
NCT05274204
Holy Stone Healthcare Co., Ltd
Advanced or Metastatic Colorectal Cancer (mCRC)
Updated: 2023-02-27
Related Papers
Phase 1 study of the safety, pharmacokinetics, and preliminary efficacy of CA102N as monotherapy and in combination with trifluridine-tipiracil in patients with locally advanced or metastatic solid tumors.
2022-11-04
3 citations